Late Breaking Abstracts Submission Rules
1. Abstracts will not be accepted unless they are submitted online via the online abstract submission system before midnight (GMT), Wednesday, July 20, 2016. Abstracts received after this date will NOT be accepted. Abstracts submitted by post, fax or email will not be considered.
2. All abstracts should be written, submitted and presented in English with a maximum word count of 300 words (not including the abstract title, authors and institutions).
3. Authors will be notified in writing by early August 2016 as to whether or not their abstract has been approved by the Abstract Review Committee (ARC). The decision of the ARC is final and no correspondence will be entered into.
4. Once an abstract has been approved, the presenting author must register for the entire congress for final acceptance. An abstract presenter may not register as a day delegate. Non-registered authors may be excluded from publication in the 12th ECE Final Programme.
5. Abstracts accepted and presented at the congress will be published, subject to editorial review, in the 12th ECE Final Programme. Selected abstracts also may be published in Epilepsia.
6. Instructions for both platform and poster presentations will be available on the congress website. Authors selected for oral presentations should use Microsoft PowerPoint only (PC Format).
7. All correspondence will be sent to the submitting author only. It is the responsibility of the submitting author to forward any relevant correspondence to the presenting author.
8. Each author is permitted to present once (not including invited lectures).
Late Breaking Abstract Content Rules
1. Abstract submitters should ensure that the version sent is the final one; changes will not be permitted once the deadline has passed.
2. Institution information should be provided for all authors. Please include institution, city, state/province and country but exclude department, division, laboratory, etc.
3. You will be required to select a category for your abstract from a drop down menu; the abstract categories for the 12th ECE are as follows:
1. Alternative therapies
2. Antiepileptic drugs
3. Basic science - models
4. Basic science - mechanisms
5. Basic science - biomarkers
6. Basic science – treatments
7. Cortical dysplasia and developmental epilepsy
9. Clinical neurophysiology
10. Clinical semiology
11. Clinical drug trials
12. Clinical pharmacology and therapeutics
13. Drug pharmacokinetics
15. Epilepsy and development
16. Epilepsy in the elderly
17. Epilepsy and women
18. Epilepsy in childhood
19. Learning disability and epilepsy
20. Epilepsy syndromes
21. Epileptic encephalopathies
23. Genetics (including genetic causes, pharmacogenetics and basic genetics)
24. Neonatal seizures/syndromes
28. Neuropsychology of epilepsy
29. Non-epileptic paroxysmal events
30. Organization of care
31. Prognosis and outcome
32. Seizure provoking factors in epilepsy
33. Psychiatry and epilepsy
34. Social issues
35. Status epilepticus
36. Surgical treatment
4. Abstracts should be structured in 4 sections as follows:
Purpose: Should indicate the objectives of the work being presented.
Method: Should describe study material or subjects (e.g. number and type of patients), intervention and evaluation procedures.
Results: Should summarize the main findings. Wherever possible, give numerical values, including means with SD or SEM, and statistical significance or confidence intervals.
Conclusion: Should state briefly the conclusions reached in the work.
5. Figures, tables and other illustrations cannot be included.
6. If the work was supported by funds provided by a commercial organization this should be stated in a short acknowledgment at the end of the abstract. Other sources of funding may be acknowledged in the same way.
7. Multiple submissions of abstracts describing different components of the same study is not appropriate. All findings generated from the same study should be included in a single abstract.
8. Abstracts containing single case reports will not usually be accepted, unless the report is of outstanding scientific or clinical interest because of the uniqueness of the findings or the sophistication of the investigations.
9. Abstracts containing data considered to be insufficiently informative will not be accepted.
10. Authors should use a concise title that indicates the content of the abstract. Abbreviations should be avoided in the title.
11. For intervention studies (for example, therapeutic trials), type of design (prospective or retrospective, controlled or uncontrolled, randomized or observational, open vs. single-blind vs. double-blind), dosages, assessment methods and duration of follow-up should be specified.
12. Non-proprietary names of drugs must be used throughout. If results are considered to be specific for a given proprietary product (for example, bio-equivalence studies), the non-proprietary name must still be used, followed by the proprietary name and the name of the manufacturers in brackets.
13. Abbreviations should be used sparingly. For words that are abbreviated, use the whole term the first time, followed by the standard abbreviation in parenthesis.
14. References should be used sparingly. They should be included within the text in brackets. For journals, mention first author "et al" followed by the name of the journal as abbreviated in the Index Medicus, year, volume number and inclusive pages (i.e. Hardus P et al. Epilepsia 2001;42:262-267.). For book chapters, give first author "et al", editor, title, publisher, city of publication, year and inclusive pages (i.e. Levy RH et al. In: Levy RH et al, Antiepileptic Drugs. Lippincott-Raven, 1996;13-30.).
15. Submission of an abstract automatically implies acknowledgment that the work described was conducted in accordance with current ethical standards and regulations in biomedical research. Failure to adhere to these standards will result in rejection of the abstract.